nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—PTGS2—skin cancer	0.377	1	CbGaD
Pomalidomide—CYP1A2—Imiquimod—skin cancer	0.085	0.196	CbGbCtD
Pomalidomide—ABCB1—Vismodegib—skin cancer	0.0515	0.119	CbGbCtD
Pomalidomide—CYP1A2—Vemurafenib—skin cancer	0.0465	0.107	CbGbCtD
Pomalidomide—CYP3A4—Imiquimod—skin cancer	0.0445	0.103	CbGbCtD
Pomalidomide—CYP3A4—Temozolomide—skin cancer	0.0445	0.103	CbGbCtD
Pomalidomide—CYP1A2—Dacarbazine—skin cancer	0.0357	0.0824	CbGbCtD
Pomalidomide—CYP3A4—Vismodegib—skin cancer	0.0309	0.0712	CbGbCtD
Pomalidomide—ABCB1—Dactinomycin—skin cancer	0.027	0.0624	CbGbCtD
Pomalidomide—CYP3A4—Vemurafenib—skin cancer	0.0244	0.0563	CbGbCtD
Pomalidomide—CYP1A2—Fluorouracil—skin cancer	0.0209	0.0483	CbGbCtD
Pomalidomide—ABCB1—Docetaxel—skin cancer	0.014	0.0322	CbGbCtD
Pomalidomide—CYP3A4—Docetaxel—skin cancer	0.00837	0.0193	CbGbCtD
Pomalidomide—CRBN—nipple—skin cancer	0.00201	0.102	CbGeAlD
Pomalidomide—Lenalidomide—PTGS2—skin cancer	0.00189	0.625	CrCbGaD
Pomalidomide—PTGS2—leg—skin cancer	0.00178	0.0899	CbGeAlD
Pomalidomide—PTGS2—hindlimb—skin cancer	0.00159	0.0803	CbGeAlD
Pomalidomide—PTGS2—appendage—skin cancer	0.00136	0.0688	CbGeAlD
Pomalidomide—TNF—lymph node—skin cancer	0.00123	0.0623	CbGeAlD
Pomalidomide—CRBN—mammalian vulva—skin cancer	0.00118	0.0594	CbGeAlD
Pomalidomide—Thalidomide—PTGS2—skin cancer	0.00113	0.375	CrCbGaD
Pomalidomide—PTGS2—skin epidermis—skin cancer	0.00113	0.0573	CbGeAlD
Pomalidomide—CRBN—lymphoid tissue—skin cancer	0.00104	0.0528	CbGeAlD
Pomalidomide—CRBN—female reproductive system—skin cancer	0.00101	0.0509	CbGeAlD
Pomalidomide—CRBN—head—skin cancer	0.000841	0.0425	CbGeAlD
Pomalidomide—PTGS2—endothelium—skin cancer	0.000822	0.0416	CbGeAlD
Pomalidomide—PTGS2—blood vessel—skin cancer	0.000758	0.0383	CbGeAlD
Pomalidomide—CYP1A2—nipple—skin cancer	0.000662	0.0335	CbGeAlD
Pomalidomide—CRBN—lymph node—skin cancer	0.000589	0.0298	CbGeAlD
Pomalidomide—ABCB1—blood vessel—skin cancer	0.000469	0.0237	CbGeAlD
Pomalidomide—Skin disorder—Vemurafenib—skin cancer	0.000415	0.00249	CcSEcCtD
Pomalidomide—Dehydration—Temozolomide—skin cancer	0.000414	0.00247	CcSEcCtD
Pomalidomide—Weight decreased—Bleomycin—skin cancer	0.000412	0.00247	CcSEcCtD
Pomalidomide—Nausea—Vismodegib—skin cancer	0.000411	0.00246	CcSEcCtD
Pomalidomide—Pneumonia—Bleomycin—skin cancer	0.000409	0.00245	CcSEcCtD
Pomalidomide—Dry skin—Temozolomide—skin cancer	0.000408	0.00244	CcSEcCtD
Pomalidomide—Pulmonary embolism—Docetaxel—skin cancer	0.000408	0.00244	CcSEcCtD
Pomalidomide—Hypokalaemia—Temozolomide—skin cancer	0.000405	0.00242	CcSEcCtD
Pomalidomide—Pancytopenia—Dactinomycin—skin cancer	0.000404	0.00241	CcSEcCtD
Pomalidomide—Breast disorder—Temozolomide—skin cancer	0.000402	0.0024	CcSEcCtD
Pomalidomide—Neutropenia—Dactinomycin—skin cancer	0.000397	0.00238	CcSEcCtD
Pomalidomide—Muscular weakness—Temozolomide—skin cancer	0.000392	0.00235	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Temozolomide—skin cancer	0.000392	0.00235	CcSEcCtD
Pomalidomide—Cough—Imiquimod—skin cancer	0.00039	0.00233	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00039	0.00233	CcSEcCtD
Pomalidomide—PTGS2—connective tissue—skin cancer	0.000389	0.0197	CbGeAlD
Pomalidomide—Neuropathy—Docetaxel—skin cancer	0.000383	0.00229	CcSEcCtD
Pomalidomide—Pneumonia—Dactinomycin—skin cancer	0.000381	0.00228	CcSEcCtD
Pomalidomide—Arthralgia—Imiquimod—skin cancer	0.000381	0.00228	CcSEcCtD
Pomalidomide—Anxiety—Imiquimod—skin cancer	0.000379	0.00227	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000378	0.00226	CcSEcCtD
Pomalidomide—Dry skin—Fluorouracil—skin cancer	0.000376	0.00225	CcSEcCtD
Pomalidomide—Decreased appetite—Vemurafenib—skin cancer	0.000372	0.00222	CcSEcCtD
Pomalidomide—Bronchitis—Temozolomide—skin cancer	0.00037	0.00221	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000369	0.00221	CcSEcCtD
Pomalidomide—PTGS2—epithelium—skin cancer	0.000369	0.0187	CbGeAlD
Pomalidomide—Fatigue—Vemurafenib—skin cancer	0.000369	0.00221	CcSEcCtD
Pomalidomide—Nasopharyngitis—Fluorouracil—skin cancer	0.000366	0.00219	CcSEcCtD
Pomalidomide—Constipation—Vemurafenib—skin cancer	0.000366	0.00219	CcSEcCtD
Pomalidomide—Pancytopenia—Temozolomide—skin cancer	0.000365	0.00218	CcSEcCtD
Pomalidomide—Infection—Imiquimod—skin cancer	0.000362	0.00217	CcSEcCtD
Pomalidomide—Muscular weakness—Fluorouracil—skin cancer	0.000361	0.00216	CcSEcCtD
Pomalidomide—Neutropenia—Temozolomide—skin cancer	0.000359	0.00215	CcSEcCtD
Pomalidomide—Nervous system disorder—Imiquimod—skin cancer	0.000358	0.00214	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Temozolomide—skin cancer	0.000357	0.00214	CcSEcCtD
Pomalidomide—Skin disorder—Imiquimod—skin cancer	0.000354	0.00212	CcSEcCtD
Pomalidomide—Sepsis—Docetaxel—skin cancer	0.000354	0.00212	CcSEcCtD
Pomalidomide—Hyperhidrosis—Imiquimod—skin cancer	0.000353	0.00211	CcSEcCtD
Pomalidomide—PTGS2—skin of body—skin cancer	0.000351	0.0177	CbGeAlD
Pomalidomide—Weight increased—Temozolomide—skin cancer	0.00035	0.00209	CcSEcCtD
Pomalidomide—Weight decreased—Temozolomide—skin cancer	0.000348	0.00208	CcSEcCtD
Pomalidomide—Hyperglycaemia—Temozolomide—skin cancer	0.000347	0.00207	CcSEcCtD
Pomalidomide—Pneumonia—Temozolomide—skin cancer	0.000345	0.00206	CcSEcCtD
Pomalidomide—Infestation—Temozolomide—skin cancer	0.000343	0.00205	CcSEcCtD
Pomalidomide—Infestation NOS—Temozolomide—skin cancer	0.000343	0.00205	CcSEcCtD
Pomalidomide—Body temperature increased—Vemurafenib—skin cancer	0.000338	0.00202	CcSEcCtD
Pomalidomide—Pancytopenia—Fluorouracil—skin cancer	0.000336	0.00201	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Temozolomide—skin cancer	0.000336	0.00201	CcSEcCtD
Pomalidomide—Urinary tract infection—Temozolomide—skin cancer	0.000333	0.00199	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000332	0.00199	CcSEcCtD
Pomalidomide—Insomnia—Imiquimod—skin cancer	0.00033	0.00197	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Fluorouracil—skin cancer	0.000329	0.00197	CcSEcCtD
Pomalidomide—Chills—Bleomycin—skin cancer	0.000327	0.00196	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Docetaxel—skin cancer	0.000326	0.00195	CcSEcCtD
Pomalidomide—Dyspnoea—Imiquimod—skin cancer	0.000325	0.00195	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Temozolomide—skin cancer	0.000324	0.00194	CcSEcCtD
Pomalidomide—Pneumonia—Fluorouracil—skin cancer	0.000318	0.0019	CcSEcCtD
Pomalidomide—Decreased appetite—Imiquimod—skin cancer	0.000317	0.0019	CcSEcCtD
Pomalidomide—Infestation—Fluorouracil—skin cancer	0.000316	0.00189	CcSEcCtD
Pomalidomide—Infestation NOS—Fluorouracil—skin cancer	0.000316	0.00189	CcSEcCtD
Pomalidomide—Hypersensitivity—Vemurafenib—skin cancer	0.000315	0.00189	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Imiquimod—skin cancer	0.000315	0.00188	CcSEcCtD
Pomalidomide—Fatigue—Imiquimod—skin cancer	0.000315	0.00188	CcSEcCtD
Pomalidomide—Atrial fibrillation—Docetaxel—skin cancer	0.000312	0.00187	CcSEcCtD
Pomalidomide—Pain—Imiquimod—skin cancer	0.000312	0.00187	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Fluorouracil—skin cancer	0.00031	0.00185	CcSEcCtD
Pomalidomide—Urinary tract infection—Fluorouracil—skin cancer	0.000307	0.00184	CcSEcCtD
Pomalidomide—Asthenia—Vemurafenib—skin cancer	0.000307	0.00184	CcSEcCtD
Pomalidomide—Chills—Dactinomycin—skin cancer	0.000305	0.00183	CcSEcCtD
Pomalidomide—Urinary tract disorder—Temozolomide—skin cancer	0.000304	0.00182	CcSEcCtD
Pomalidomide—Oedema peripheral—Temozolomide—skin cancer	0.000303	0.00181	CcSEcCtD
Pomalidomide—Pruritus—Vemurafenib—skin cancer	0.000303	0.00181	CcSEcCtD
Pomalidomide—Connective tissue disorder—Temozolomide—skin cancer	0.000302	0.00181	CcSEcCtD
Pomalidomide—Urethral disorder—Temozolomide—skin cancer	0.000302	0.0018	CcSEcCtD
Pomalidomide—Feeling abnormal—Imiquimod—skin cancer	0.000301	0.0018	CcSEcCtD
Pomalidomide—Epistaxis—Fluorouracil—skin cancer	0.000298	0.00178	CcSEcCtD
Pomalidomide—Hyponatraemia—Docetaxel—skin cancer	0.000297	0.00178	CcSEcCtD
Pomalidomide—Pain in extremity—Docetaxel—skin cancer	0.000296	0.00177	CcSEcCtD
Pomalidomide—Anaemia—Bleomycin—skin cancer	0.000294	0.00176	CcSEcCtD
Pomalidomide—Diarrhoea—Vemurafenib—skin cancer	0.000293	0.00175	CcSEcCtD
Pomalidomide—Body temperature increased—Imiquimod—skin cancer	0.000288	0.00173	CcSEcCtD
Pomalidomide—Cardiac disorder—Temozolomide—skin cancer	0.000286	0.00171	CcSEcCtD
Pomalidomide—PTGS2—lymphoid tissue—skin cancer	0.000284	0.0144	CbGeAlD
Pomalidomide—Leukopenia—Bleomycin—skin cancer	0.000284	0.0017	CcSEcCtD
Pomalidomide—Dizziness—Vemurafenib—skin cancer	0.000283	0.00169	CcSEcCtD
Pomalidomide—Angiopathy—Temozolomide—skin cancer	0.000279	0.00167	CcSEcCtD
Pomalidomide—Mediastinal disorder—Temozolomide—skin cancer	0.000277	0.00166	CcSEcCtD
Pomalidomide—Cough—Bleomycin—skin cancer	0.000277	0.00166	CcSEcCtD
Pomalidomide—Chills—Temozolomide—skin cancer	0.000276	0.00165	CcSEcCtD
Pomalidomide—Dehydration—Docetaxel—skin cancer	0.000275	0.00165	CcSEcCtD
Pomalidomide—PTGS2—female reproductive system—skin cancer	0.000274	0.0139	CbGeAlD
Pomalidomide—Anaemia—Dactinomycin—skin cancer	0.000274	0.00164	CcSEcCtD
Pomalidomide—Vomiting—Vemurafenib—skin cancer	0.000272	0.00163	CcSEcCtD
Pomalidomide—Dry skin—Docetaxel—skin cancer	0.000271	0.00162	CcSEcCtD
Pomalidomide—Rash—Vemurafenib—skin cancer	0.00027	0.00161	CcSEcCtD
Pomalidomide—Mental disorder—Temozolomide—skin cancer	0.00027	0.00161	CcSEcCtD
Pomalidomide—Dermatitis—Vemurafenib—skin cancer	0.000269	0.00161	CcSEcCtD
Pomalidomide—Hypersensitivity—Imiquimod—skin cancer	0.000269	0.00161	CcSEcCtD
Pomalidomide—Headache—Vemurafenib—skin cancer	0.000268	0.0016	CcSEcCtD
Pomalidomide—Malnutrition—Temozolomide—skin cancer	0.000268	0.0016	CcSEcCtD
Pomalidomide—Breast disorder—Docetaxel—skin cancer	0.000267	0.0016	CcSEcCtD
Pomalidomide—Leukopenia—Dactinomycin—skin cancer	0.000265	0.00159	CcSEcCtD
Pomalidomide—Nasopharyngitis—Docetaxel—skin cancer	0.000265	0.00158	CcSEcCtD
Pomalidomide—Asthenia—Imiquimod—skin cancer	0.000262	0.00157	CcSEcCtD
Pomalidomide—Confusional state—Bleomycin—skin cancer	0.000261	0.00156	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000261	0.00156	CcSEcCtD
Pomalidomide—Back pain—Temozolomide—skin cancer	0.000259	0.00155	CcSEcCtD
Pomalidomide—Pruritus—Imiquimod—skin cancer	0.000258	0.00154	CcSEcCtD
Pomalidomide—Infection—Bleomycin—skin cancer	0.000257	0.00154	CcSEcCtD
Pomalidomide—Nausea—Vemurafenib—skin cancer	0.000254	0.00152	CcSEcCtD
Pomalidomide—Thrombocytopenia—Bleomycin—skin cancer	0.000254	0.00152	CcSEcCtD
Pomalidomide—Tremor—Temozolomide—skin cancer	0.000251	0.0015	CcSEcCtD
Pomalidomide—Diarrhoea—Imiquimod—skin cancer	0.00025	0.00149	CcSEcCtD
Pomalidomide—Anaemia—Temozolomide—skin cancer	0.000248	0.00148	CcSEcCtD
Pomalidomide—Pancytopenia—Docetaxel—skin cancer	0.000243	0.00145	CcSEcCtD
Pomalidomide—Dizziness—Imiquimod—skin cancer	0.000241	0.00144	CcSEcCtD
Pomalidomide—Vertigo—Temozolomide—skin cancer	0.000241	0.00144	CcSEcCtD
Pomalidomide—Infection—Dactinomycin—skin cancer	0.00024	0.00144	CcSEcCtD
Pomalidomide—Leukopenia—Temozolomide—skin cancer	0.00024	0.00143	CcSEcCtD
Pomalidomide—CYP3A4—female reproductive system—skin cancer	0.00024	0.0121	CbGeAlD
Pomalidomide—Neutropenia—Docetaxel—skin cancer	0.000239	0.00143	CcSEcCtD
Pomalidomide—Thrombocytopenia—Dactinomycin—skin cancer	0.000237	0.00142	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000236	0.00141	CcSEcCtD
Pomalidomide—Cough—Temozolomide—skin cancer	0.000234	0.0014	CcSEcCtD
Pomalidomide—Weight increased—Docetaxel—skin cancer	0.000233	0.00139	CcSEcCtD
Pomalidomide—Vomiting—Imiquimod—skin cancer	0.000232	0.00139	CcSEcCtD
Pomalidomide—Weight decreased—Docetaxel—skin cancer	0.000231	0.00138	CcSEcCtD
Pomalidomide—Dyspnoea—Bleomycin—skin cancer	0.000231	0.00138	CcSEcCtD
Pomalidomide—Rash—Imiquimod—skin cancer	0.00023	0.00138	CcSEcCtD
Pomalidomide—Dermatitis—Imiquimod—skin cancer	0.00023	0.00137	CcSEcCtD
Pomalidomide—Pneumonia—Docetaxel—skin cancer	0.000229	0.00137	CcSEcCtD
Pomalidomide—PTGS2—head—skin cancer	0.000229	0.0116	CbGeAlD
Pomalidomide—Headache—Imiquimod—skin cancer	0.000229	0.00137	CcSEcCtD
Pomalidomide—ABCB1—epithelium—skin cancer	0.000228	0.0115	CbGeAlD
Pomalidomide—Anaemia—Fluorouracil—skin cancer	0.000228	0.00136	CcSEcCtD
Pomalidomide—Arthralgia—Temozolomide—skin cancer	0.000228	0.00136	CcSEcCtD
Pomalidomide—Infestation NOS—Docetaxel—skin cancer	0.000228	0.00136	CcSEcCtD
Pomalidomide—Infestation—Docetaxel—skin cancer	0.000228	0.00136	CcSEcCtD
Pomalidomide—Anxiety—Temozolomide—skin cancer	0.000227	0.00136	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000226	0.00135	CcSEcCtD
Pomalidomide—Decreased appetite—Bleomycin—skin cancer	0.000225	0.00135	CcSEcCtD
Pomalidomide—Renal failure—Docetaxel—skin cancer	0.000224	0.00134	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Docetaxel—skin cancer	0.000223	0.00134	CcSEcCtD
Pomalidomide—Pain—Bleomycin—skin cancer	0.000222	0.00133	CcSEcCtD
Pomalidomide—Leukopenia—Fluorouracil—skin cancer	0.000221	0.00132	CcSEcCtD
Pomalidomide—Confusional state—Temozolomide—skin cancer	0.00022	0.00132	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00022	0.00132	CcSEcCtD
Pomalidomide—Infection—Temozolomide—skin cancer	0.000217	0.0013	CcSEcCtD
Pomalidomide—Nausea—Imiquimod—skin cancer	0.000217	0.0013	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Docetaxel—skin cancer	0.000216	0.00129	CcSEcCtD
Pomalidomide—Epistaxis—Docetaxel—skin cancer	0.000215	0.00129	CcSEcCtD
Pomalidomide—Nervous system disorder—Temozolomide—skin cancer	0.000214	0.00128	CcSEcCtD
Pomalidomide—Thrombocytopenia—Temozolomide—skin cancer	0.000214	0.00128	CcSEcCtD
Pomalidomide—Feeling abnormal—Bleomycin—skin cancer	0.000214	0.00128	CcSEcCtD
Pomalidomide—Skin disorder—Temozolomide—skin cancer	0.000212	0.00127	CcSEcCtD
Pomalidomide—Hyperhidrosis—Temozolomide—skin cancer	0.000211	0.00126	CcSEcCtD
Pomalidomide—Decreased appetite—Dactinomycin—skin cancer	0.00021	0.00126	CcSEcCtD
Pomalidomide—Fatigue—Dactinomycin—skin cancer	0.000208	0.00125	CcSEcCtD
Pomalidomide—Pain—Dactinomycin—skin cancer	0.000207	0.00124	CcSEcCtD
Pomalidomide—Body temperature increased—Bleomycin—skin cancer	0.000205	0.00123	CcSEcCtD
Pomalidomide—Confusional state—Fluorouracil—skin cancer	0.000203	0.00122	CcSEcCtD
Pomalidomide—Urinary tract disorder—Docetaxel—skin cancer	0.000202	0.00121	CcSEcCtD
Pomalidomide—Oedema peripheral—Docetaxel—skin cancer	0.000202	0.00121	CcSEcCtD
Pomalidomide—Connective tissue disorder—Docetaxel—skin cancer	0.000201	0.0012	CcSEcCtD
Pomalidomide—Urethral disorder—Docetaxel—skin cancer	0.000201	0.0012	CcSEcCtD
Pomalidomide—Infection—Fluorouracil—skin cancer	0.0002	0.0012	CcSEcCtD
Pomalidomide—Feeling abnormal—Dactinomycin—skin cancer	0.000199	0.00119	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000199	0.00119	CcSEcCtD
Pomalidomide—ABCB1—mammalian vulva—skin cancer	0.000198	0.01	CbGeAlD
Pomalidomide—Insomnia—Temozolomide—skin cancer	0.000198	0.00118	CcSEcCtD
Pomalidomide—Nervous system disorder—Fluorouracil—skin cancer	0.000198	0.00118	CcSEcCtD
Pomalidomide—Thrombocytopenia—Fluorouracil—skin cancer	0.000197	0.00118	CcSEcCtD
Pomalidomide—Dyspnoea—Temozolomide—skin cancer	0.000195	0.00117	CcSEcCtD
Pomalidomide—Body temperature increased—Dactinomycin—skin cancer	0.000191	0.00114	CcSEcCtD
Pomalidomide—Hypersensitivity—Bleomycin—skin cancer	0.000191	0.00114	CcSEcCtD
Pomalidomide—Decreased appetite—Temozolomide—skin cancer	0.00019	0.00114	CcSEcCtD
Pomalidomide—Cardiac disorder—Docetaxel—skin cancer	0.00019	0.00114	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Temozolomide—skin cancer	0.000189	0.00113	CcSEcCtD
Pomalidomide—Fatigue—Temozolomide—skin cancer	0.000188	0.00113	CcSEcCtD
Pomalidomide—Pain—Temozolomide—skin cancer	0.000187	0.00112	CcSEcCtD
Pomalidomide—Constipation—Temozolomide—skin cancer	0.000187	0.00112	CcSEcCtD
Pomalidomide—Asthenia—Bleomycin—skin cancer	0.000186	0.00111	CcSEcCtD
Pomalidomide—Angiopathy—Docetaxel—skin cancer	0.000186	0.00111	CcSEcCtD
Pomalidomide—Mediastinal disorder—Docetaxel—skin cancer	0.000184	0.0011	CcSEcCtD
Pomalidomide—Chills—Docetaxel—skin cancer	0.000184	0.0011	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000184	0.0011	CcSEcCtD
Pomalidomide—Pruritus—Bleomycin—skin cancer	0.000183	0.0011	CcSEcCtD
Pomalidomide—Insomnia—Fluorouracil—skin cancer	0.000182	0.00109	CcSEcCtD
Pomalidomide—Feeling abnormal—Temozolomide—skin cancer	0.00018	0.00108	CcSEcCtD
Pomalidomide—Dyspnoea—Fluorouracil—skin cancer	0.00018	0.00107	CcSEcCtD
Pomalidomide—Mental disorder—Docetaxel—skin cancer	0.000179	0.00107	CcSEcCtD
Pomalidomide—Malnutrition—Docetaxel—skin cancer	0.000178	0.00107	CcSEcCtD
Pomalidomide—Hypersensitivity—Dactinomycin—skin cancer	0.000178	0.00107	CcSEcCtD
Pomalidomide—ABCB1—lymphoid tissue—skin cancer	0.000176	0.00889	CbGeAlD
Pomalidomide—Decreased appetite—Fluorouracil—skin cancer	0.000175	0.00105	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000174	0.00104	CcSEcCtD
Pomalidomide—Asthenia—Dactinomycin—skin cancer	0.000173	0.00104	CcSEcCtD
Pomalidomide—Body temperature increased—Temozolomide—skin cancer	0.000173	0.00103	CcSEcCtD
Pomalidomide—Back pain—Docetaxel—skin cancer	0.000172	0.00103	CcSEcCtD
Pomalidomide—Pain—Fluorouracil—skin cancer	0.000172	0.00103	CcSEcCtD
Pomalidomide—Muscle spasms—Docetaxel—skin cancer	0.000171	0.00102	CcSEcCtD
Pomalidomide—ABCB1—female reproductive system—skin cancer	0.00017	0.00857	CbGeAlD
Pomalidomide—Feeling abnormal—Fluorouracil—skin cancer	0.000166	0.000993	CcSEcCtD
Pomalidomide—Diarrhoea—Dactinomycin—skin cancer	0.000165	0.000989	CcSEcCtD
Pomalidomide—Vomiting—Bleomycin—skin cancer	0.000165	0.000986	CcSEcCtD
Pomalidomide—Anaemia—Docetaxel—skin cancer	0.000165	0.000985	CcSEcCtD
Pomalidomide—Rash—Bleomycin—skin cancer	0.000163	0.000978	CcSEcCtD
Pomalidomide—Dermatitis—Bleomycin—skin cancer	0.000163	0.000977	CcSEcCtD
Pomalidomide—Hypersensitivity—Temozolomide—skin cancer	0.000161	0.000964	CcSEcCtD
Pomalidomide—PTGS2—lymph node—skin cancer	0.00016	0.00811	CbGeAlD
Pomalidomide—Leukopenia—Docetaxel—skin cancer	0.000159	0.000954	CcSEcCtD
Pomalidomide—Body temperature increased—Fluorouracil—skin cancer	0.000159	0.000953	CcSEcCtD
Pomalidomide—Asthenia—Temozolomide—skin cancer	0.000157	0.000938	CcSEcCtD
Pomalidomide—Cough—Docetaxel—skin cancer	0.000155	0.00093	CcSEcCtD
Pomalidomide—Pruritus—Temozolomide—skin cancer	0.000155	0.000925	CcSEcCtD
Pomalidomide—Nausea—Bleomycin—skin cancer	0.000154	0.000921	CcSEcCtD
Pomalidomide—Vomiting—Dactinomycin—skin cancer	0.000154	0.000919	CcSEcCtD
Pomalidomide—Rash—Dactinomycin—skin cancer	0.000152	0.000912	CcSEcCtD
Pomalidomide—Arthralgia—Docetaxel—skin cancer	0.000152	0.000907	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000151	0.000901	CcSEcCtD
Pomalidomide—Diarrhoea—Temozolomide—skin cancer	0.00015	0.000895	CcSEcCtD
Pomalidomide—Hypersensitivity—Fluorouracil—skin cancer	0.000148	0.000888	CcSEcCtD
Pomalidomide—Confusional state—Docetaxel—skin cancer	0.000147	0.000877	CcSEcCtD
Pomalidomide—Dizziness—Temozolomide—skin cancer	0.000145	0.000865	CcSEcCtD
Pomalidomide—Infection—Docetaxel—skin cancer	0.000144	0.000864	CcSEcCtD
Pomalidomide—Nausea—Dactinomycin—skin cancer	0.000144	0.000859	CcSEcCtD
Pomalidomide—Nervous system disorder—Docetaxel—skin cancer	0.000143	0.000853	CcSEcCtD
Pomalidomide—Pruritus—Fluorouracil—skin cancer	0.000143	0.000853	CcSEcCtD
Pomalidomide—Thrombocytopenia—Docetaxel—skin cancer	0.000142	0.000852	CcSEcCtD
Pomalidomide—ABCB1—head—skin cancer	0.000142	0.00716	CbGeAlD
Pomalidomide—Skin disorder—Docetaxel—skin cancer	0.000141	0.000845	CcSEcCtD
Pomalidomide—Vomiting—Temozolomide—skin cancer	0.000139	0.000832	CcSEcCtD
Pomalidomide—Rash—Temozolomide—skin cancer	0.000138	0.000825	CcSEcCtD
Pomalidomide—Diarrhoea—Fluorouracil—skin cancer	0.000138	0.000825	CcSEcCtD
Pomalidomide—Dermatitis—Temozolomide—skin cancer	0.000138	0.000824	CcSEcCtD
Pomalidomide—Headache—Temozolomide—skin cancer	0.000137	0.000819	CcSEcCtD
Pomalidomide—Dizziness—Fluorouracil—skin cancer	0.000133	0.000797	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000132	0.000792	CcSEcCtD
Pomalidomide—Insomnia—Docetaxel—skin cancer	0.000131	0.000787	CcSEcCtD
Pomalidomide—Nausea—Temozolomide—skin cancer	0.00013	0.000777	CcSEcCtD
Pomalidomide—Dyspnoea—Docetaxel—skin cancer	0.00013	0.000775	CcSEcCtD
Pomalidomide—Vomiting—Fluorouracil—skin cancer	0.000128	0.000766	CcSEcCtD
Pomalidomide—Rash—Fluorouracil—skin cancer	0.000127	0.00076	CcSEcCtD
Pomalidomide—Dermatitis—Fluorouracil—skin cancer	0.000127	0.000759	CcSEcCtD
Pomalidomide—Decreased appetite—Docetaxel—skin cancer	0.000126	0.000756	CcSEcCtD
Pomalidomide—Headache—Fluorouracil—skin cancer	0.000126	0.000755	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Docetaxel—skin cancer	0.000126	0.000751	CcSEcCtD
Pomalidomide—Fatigue—Docetaxel—skin cancer	0.000125	0.00075	CcSEcCtD
Pomalidomide—Pain—Docetaxel—skin cancer	0.000124	0.000744	CcSEcCtD
Pomalidomide—Constipation—Docetaxel—skin cancer	0.000124	0.000744	CcSEcCtD
Pomalidomide—Feeling abnormal—Docetaxel—skin cancer	0.00012	0.000717	CcSEcCtD
Pomalidomide—Nausea—Fluorouracil—skin cancer	0.00012	0.000716	CcSEcCtD
Pomalidomide—Body temperature increased—Docetaxel—skin cancer	0.000115	0.000688	CcSEcCtD
Pomalidomide—Hypersensitivity—Docetaxel—skin cancer	0.000107	0.000641	CcSEcCtD
Pomalidomide—Asthenia—Docetaxel—skin cancer	0.000104	0.000624	CcSEcCtD
Pomalidomide—Pruritus—Docetaxel—skin cancer	0.000103	0.000615	CcSEcCtD
Pomalidomide—Diarrhoea—Docetaxel—skin cancer	9.95e-05	0.000595	CcSEcCtD
Pomalidomide—ABCB1—lymph node—skin cancer	9.92e-05	0.00501	CbGeAlD
Pomalidomide—Dizziness—Docetaxel—skin cancer	9.61e-05	0.000575	CcSEcCtD
Pomalidomide—Vomiting—Docetaxel—skin cancer	9.24e-05	0.000553	CcSEcCtD
Pomalidomide—Rash—Docetaxel—skin cancer	9.17e-05	0.000548	CcSEcCtD
Pomalidomide—Dermatitis—Docetaxel—skin cancer	9.16e-05	0.000548	CcSEcCtD
Pomalidomide—Headache—Docetaxel—skin cancer	9.11e-05	0.000545	CcSEcCtD
Pomalidomide—Nausea—Docetaxel—skin cancer	8.64e-05	0.000517	CcSEcCtD
